Page 10 - Zydus Lifesciences

Zydus receives final approval from USFDA for esomeprazole magnesium

Esomeprazole magnesium for delayed-release oral suspension, 20 mg and 40 mg had annual sales of $42 mn in the United States

Stocks to Watch today, June 8: Banks, Auto, Lemon Tree, Adani Ent, Titagarh

Stocks to Watch on June 8, 2023: Shares of banks, automobile, and real estate companies could see considerable action in Thursday's session as the Reserve Bank of India (RBI) is slated to announce its

Zydus Lifesciences Q4 consolidated net profit dips 25.36% to Rs 296.6 cr

Zydus Lifesciences Ltd on Thursday reported a 25.36 per cent decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the Annual General Meeting scheduled to be held on August 11, 2023. Consolidated total revenue from operations stood at Rs 5,010.6 crore, as against Rs 3,805.6 crore in the corresponding period a year ago, Zydus Lifesciences said in a regulatory filing. Total expenses were higher at Rs 3,961.3 crore, as compared to Rs 3,311.8 crore in the year-ago quarter. During the quarter, Zydus Lifesciences said it incurred an exceptional item of Rs 594.1 crore as impairment of goodwill by Sentynl Therapeutics Inc, a wholly-owned subsidi

Zydus Lifesciences gets final approval from USFDA to manufacture ulcer drug

Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States

ACC, Nykaa, HDFC AMC and Muthoot Fin likely to be dropped from Nifty 100

Jindal Steel and Power, Punjab National Bank, TVS Motor, Tube Investments and Zydus Lifesciences are expected to get added to the index

Zydus Lifesciences gets nod from USFDA for metronidazole topical cream

The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad

Escorts, Bank of India: Select midcap stocks are poised for up to 20% gains

Zydus Lifesciences, in particular, has been scaling 52-week highs with momentum staying highly elevated. Also, Aurobindo Pharma shares have seen a steeper rise, with aggressive chart structures.

Zydus Lifesciences gets USFDA nod to its generic medicine for high BP

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic version of metoprolol tartrate tablets used to treat high blood pressure. The approval granted by the United States Food and Drug Administration (USFDA) is for metoprolol tartrate tablets of strengths 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a regulatory filing. The drug will be manufactured at the group's formulation manufacturing facility at Baddi in Himachal Pradesh, it added. Metoprolol is used with or without other medications to treat high blood pressure (hypertension), the company said, adding the medication is also used to treat chest pain (angina) and to improve survival after a heart attack. Metoprolol tartrate tablets 25 mg, 50 mg, and 100 mg had annual sales of USD 45.2 million in the US, the company said citing IQVIA MAT February 2023 data.

Stocks to Watch: SBI, ICICI Lombard, ONGC, Reliance, Oil India, Zydus Life

Stocks to Watch: ICICI Lombard General Insurance reported a 39.6 per cent surge in net profit in the January-March quarter (Q4) of FY23

Zydus Lifesciences gets USFDA nod for generic female hormone in US market

Zydus Lifesciences on Tuesday said it has received approval from the US regulator to market a generic female hormone, which helps reduce symptoms of menopause, in the US market. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP in the American market. Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The company said the drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad in Gujarat. As per the IQVIA sales data, Estradiol Transdermal System had annual sales of USD 1.9 million in the US.

Booster dose: Zydus likely to arm India with single-dose malaria drug

In Phase-2 trials now, pill also works against drug-resistant malaria strains

Bulls ride on bank stocks to end higher for 7th session; Sensex up 311 pts

CLOSING BELL: The Nifty50 added 98 points to end at 17,722 level

Stocks to watch: JSW Steel, Cipla, Zydus Life, Kaveri Seed, Kalpataru Power

Stocks to watch today: From Cipla to Zydus Lifesciences, here are top stocks to watch in Tuesday's trading session

Inverse H&S in pharma index could revive a positive bias for short-term

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Sensex, Nifty trim gains amid late sell-off; RIL shines, auto stocks whine

CLOSING BELL: The S&P BSE Sensex ended 127 points higher; Among the broader indices, the Smallcap index tumbled 1.6 per cent.

Stocks to watch: Tata Steel, BEL, Paytm, Zydus Life, Crompton Greaves, NBCC

Stocks to watch: From Tata Steel to Bharat Electronics, here are few stocks likely to see action in Monday's trading session

Zydus recalls over 55k bottles of generic drug used to treat gout in US

Drug firm Zydus Lifesciences is recalling over 55,000 bottles of generic medication in the US market due to failed impurities specifications. As per the latest enforcement report by the US Food and Drug Administration (USFDA), Zydus Pharmaceuticals (USA) Inc is recalling 21,936 (30 count) and 33,096 (100 count) bottles of Colchicine tablets, which are used to treat gout. The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences and marketed in the US by New Jersey-based Zydus Pharmaceuticals (USA) Inc. USFDA said the company is recalling the product due to "failed impurities/ degradation specifications". An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine, it added. Zydus commenced the Class III recall on February 24 this year. As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health ...

Zydus Lifesciences gets US health regulator's nod for its generic medicine

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic doxepin hydrochloride capsules used in the treatment of depression and anxiety. The approval granted by the US Food and Drug Administration (USFDA) is for doxepin hydrochloride capsules of strength 150 mg, the company said in a regulatory filing. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, it added. Doxepin hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level, it added. The drug had annual sales of USD 2.11 million in the US, the company said citing IQVIA MAT January 2023 data.

Multiple triggers likely to help Zydus to continue with its outperformance

New launches in the US, market share gains and steady domestic growth are positives

Here's why Vinay Rajani of HDFC Sec suggests to buy Zydus Life, Coal India

Among individual stocks, the technical & derivative analyst from HDFC Securities recommends to buy Zydus Life and Coal India